Akyol, O., Zoroglu, S
At 10 active days per cycle, the total annual injection commitment at maximum frequency is only 30 days, making it one of the lowest-burden protocols in terms of active treatment time
However, regulations vary across different jurisdictions
While athletes often use peptide and vitamin therapy to support recovery and performance, many patients seek treatment to improve energy levels, healthy aging, metabolic wellness, or overall quality of life
Areas covered Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials